SEMAFIT 2

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus and obesity. It is a synthetic analog of human GLP-1 with 94% sequence homology, designed to be resistant to dipeptidyl peptidase-4 (DPP-4) degradation, thereby prolonging its half-life to approximately 1 week. Semaglutide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and reduces appetite via central nervous system pathways. It is administered via subcutaneous injection once weekly. Clinical trials (e.g., SUSTAIN and STEP programs) have demonstrated significant HbA1c reduction and meaningful weight loss in both diabetic and non-diabetic populations. Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN 2).